Skip NavigationSkip to Content
Return Return to Search Results

Small nonphosphorylated Grb2-SH2 domain antagonists evaluated by surface resonance plasmon technology

  1. Author:
    Lung, F. D. T.
    Chang, C. W.
    Chong, M. C.
    Liou, C. C.
    Li, P.
    Peach, M. L.
    Nicklaus, M. C.
    Lou, B. S.
    Roller, P. P.

  2. Author Address

    Tunghai Univ, Dept Chem, Taichung 40704, Taiwan. China Med Univ, Inst Nutr, Taichung, Taiwan. NCI, Med Chem Lab, FCRDC, Ft Detrick, MD 21702 USA. Chang Gung Univ, Ctr Gen Educ, Div Chem, Tao Yuan, Taiwan Lung, FDT, Tunghai Univ, Dept Chem, Taichung 40704, Taiwan
    1. Year: 2005
  2. Journal: Peptide Science (Biopolymers)
    1. 80
    2. 5
    3. Pages: 628-635
  4. Type of Article: Article
  1. Abstract:

    The growth factor receptor-binding protein-Src homology 2 (Grb2-SH2) domain plays an important role in the oncogenic Ras signal transduction pathway, which involves cell proliferation and differentiation. Therefore, the Grb2-SH2 domain has been chosen as our target for development of potential antiproliferative agents. Herein, we report the study of the inhibitory effects of small nonphosphorylated peptide analogs interacting with the Grb2-SH2 domain protein by surface plasmon resonance (SPR) technology. A set of 8 related peptide analogs were synthesized, purified, and characterized. Their inhibitory effects on Grb2-SH2 were evaluated by the SPR technology developed with the BIACORE X instrument. The lead peptide, Fmoc-Glu-Tyr-Aib-Asn-NH2 (Fmoc-E-Y-Aib-N,- Fmoc: 9-fluorenylmethyoxycarbonyl; Aib = alpha-amino isobutyric acid) inhibited Grb2-SH2 domain function with an IC50 value of 8.7 mu M. A molecular modeling study of the lead peptide indicated that the glutamate in the Fmoc peptide is ideally positioned to form a strong salt bridge to Arg 67 in the Grb2-SH2 domain, using both its backbone carbonyl and its acidic group. Residue Glu 89 in Grb2-SH2 flips inward to fill the binding site and partially replace the phosphate group as a hydrogen-bond acceptor. Results of these studies provide important information for further development of potent nonphosphorylated peptide inhibitors of the Grb2-SH2 domain. (C) 2005 Wiley Periodicals, Inc

    See More

  1. Keywords:

External Sources

  1. View record in Web of Science®
  2. WOS: 000232334800002

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel